Emerging therapies for acute traumatic spinal cord injury

Jefferson R. Wilson MD, Nicole Forgione PhD, Michael G. Fehlings MD PhD

There are currently about 85 000 Canadians living with spinal cord injuries, more than half of which are secondary to trauma. As the population ages, the incidence and prevalence of traumatic spinal cord injury are expected to increase, primarily as a result of fall-related injuries among older adults. Therefore, treating spinal cord injuries is relevant not only to spine surgeons and physiatrists, but also to the general clinician who will increasingly encounter such patients in the emergency department or family practice.

Here, we review relevant pathophysiology and recent evidence pertaining to the medical, surgical and cellular-based treatment of acute traumatic spinal cord injury. Most of the identified pharmacologic studies were randomized trials or early phase nonrandomized prospective studies. Research relating to the remaining topics was predominately observational in design (Box 1).

What mechanisms underlie neural injury and repair?

The initial trauma, or primary injury to the spinal cord, starts a sequence of pathological events collectively referred to as secondary injury. These secondary mechanisms begin within seconds of the primary injury and continue for several weeks thereafter, leading to an expanded region of tissue destruction (Figure 1). The initial disruption of the spinal cord vasculature leads to the development of microhemorrhages in the grey and white matter, interstitial edema and the release of coagulation factors and vasoactive amines. These events promote thrombosis and vasospasm of the microvasculature of the spinal cord causing tissue hypoxia and impaired neuronal homeostasis. At the cellular level, impairments include ionic imbalance, peroxidation of membrane lipids, formation of free radicals and release of toxic levels of the excitatory neurotransmitter glutamate. Neuroprotective agents act to mitigate secondary injury mechanisms to reduce the extent of neural damage.

The regenerative capacity of the neurons of the central nervous system (CNS) is severely limited compared with neurons in the peripheral nervous system, largely because of the production of inhibitory molecules that thwart axonal growth, preventing regeneration of injured nerve tracts. Nogo is a family of inhibitory proteins that bind to the Nogo receptor found on regenerating axons. This binding leads to the activation of the Rho pathway, causing inhibition of both axonal growth and neuronal cytoskeletal development. In contrast to neuroprotective therapies, which limit the extent of acute neural injury, neuroregenerative therapies facilitate neuronal regrowth by several mechanisms, including the blockade of these inhibitory pathways.

What supportive and surgical management is effective?

Historically, it was common for patients with spinal injuries to be placed in unmonitored beds on hospital wards for prolonged periods while elements of the bony injury healed. This approach has been supplanted by aggressive medical and surgical methods focused on maintaining cord perfusion, avoiding complications, decompressing the spinal cord and restoring spinal stability.

Medical support

The negative consequences of hypotension on the injured CNS are well established. There is consistent evidence that avoiding hypotension and...
Box 1: Evidence used in this review

We performed a comprehensive literature search of MEDLINE for the key words “spinal cord injury” and the medical subheading “treatment.” We limited the search to clinical articles published between 1980 and 2012 in English journals. We excluded studies involving animals, review articles and case reports. We supplemented this strategy by searching the Cochrane Database of Systematic Reviews for the term “spinal cord injury.” We identified and reviewed 401 abstracts for relevance to the topic. We selected 45 abstracts for which we obtained the full-text version to use as the basis for this review. In addition, we reviewed the 2002 American Association of Neurological Surgeons/Congress of Neurological Surgeons cervical spinal cord injury consensus guidelines, as well as the Consortium for Spinal Cord Medicine 2008 spinal cord injury early acute management clinical practice guidelines.

maintaining aggressive blood pressure targets during the acute phases after injury improves neurologic recovery and reduces mortality.9 Based on existing, largely retrospective data, the American Association of Neurological Surgeons recommends that patients’ mean arterial pressure be maintained at 85–90 mmHg for the first 7 days after injury.10 When volume replacement is inadequate to achieve this goal, intravenous vasopressor medications may be introduced.

Patients, particularly those with severe cervical injuries, should receive treatment in an intensive care unit (ICU) with continuous cardiac, hemodynamic and respiratory monitoring for the first 7–14 days after injury. In observational studies, the standardized admission of patients with spinal injuries to an ICU has been associated with reduced mortality and morbidity, in addition to improved neurologic recovery.11

Surgical decompression

The preclinical literature provides a strong biological imperative to decompress the spinal cord early after injury.12 In spite of compelling laboratory findings, for many years, surgeons were reluctant to operate acutely owing to concerns that perioperative hemodynamic changes would compromise cord perfusion.13 In addition, until the proliferation of instrumented spinal fixation techniques in the 1990s, decompression meant further destabilizing an already unstable spine.

Retrospective studies provide conflicting results as to the effect of early surgery on neurologic recovery, but all have shown early decompression to be safe.14 The Surgical Timing in Acute Spinal Cord Injury Study (STASCIS),15 a prospective, multicentre, nonrandomized cohort study, compared 313 patients who underwent either early (< 24 h after injury) or late (≥ 24 h after injury) surgical decompression. Early surgery was associated with better neurologic recovery at 6 months as defined by a 2-grade improvement in the American Spinal Injury Association impairment scale (odds ratio [OR] 2.57, 95% confidence interval [CI] 1.11 to 5.97), with no increase in acute complications compared with late surgery (24.2% v. 30.5%, p = 0.21). These results validate those of recent consensus surveys suggesting surgeon preference toward early decompression.16

In the specific case of dislocation of the cervical spine, rapid closed reduction of the spine using skeletal traction remains a valid treatment option. In this case, surgery is performed after closed reduction to re-establish spinal stability.

Therapeutic hypothermia

Preclinical studies have suggested that cooling mitigates secondary injury mechanisms.17 Initial clinical studies involving direct cooling of the cord during surgery failed to show any benefit. However, a recent phase I trial investigated the acute use of modest (33°C) systemic intra-vascular hypothermia.18 Complications did not differ between the 14 patients receiving the treatment and the 14 patients to whom they were matched in the control group. At 1-year follow-up, 6 of 14 patients in the treatment group (42.9%) converted from complete (no motor or sensory function below the level of injury) to incomplete (motor or sensory function present below the level of injury) status (3/14 [21.4%] of patients in the control group showed the same degree of recovery), which compares favourably with a neurologic recovery rate of 20% reported in the literature. Although there is currently insufficient evidence to support the use of systemic hypothermia, a multicentre efficacy trial exploring this therapy is being planned.

What drugs have been evaluated for treating spinal cord injury?

To date, 5 pharmacologic therapies have been evaluated in phase III trials (Table 1).19–23 None of them have become standard of care.

Neuroprotective agents

Methylprednisolone sodium succinate

Methylprednisolone, which attenuates the peroxidation of membrane lipids and post-traumatic inflammation, has consistently been associated with improved neurobehavioural outcomes in preclinical studies.24 However, the use of methylprednisolone in the clinical setting remains controversial. The most recent Cochrane review pooled the results of 3 studies (meta-analyses) and found no effect for a high-dose 24-hour infusion of methylprednisolone in terms of motor recovery at 6 months (weighted mean difference 0.85, 95% CI –1.79 to 3.49).25 However, when
started within 8 hours after injury, methylprednisolone was associated with an additional 4-point improvement in NASCIS motor score (weighted mean difference 4.06, 95% CI 0.58 to 7.55). Trends toward increased rates of gastrointestinal hemorrhage (relative risk [RR] 2.18, 95% CI 0.80 to 5.93) and wound infections (RR 2.11, 95% CI 0.81 to 5.49) were seen among patients receiving methylprednisolone. Critics of the drug cite these complications, as well as the use of subgroup analyses to prove effect, as arguments against its use. Balancing the available evidence, consensus guidelines recommend that 24-hour infusion of methylpred-

**Figure 1:** (A) Primary and secondary mechanisms of injury determining the final extent of spinal cord damage. The primary injury event starts a pathobiological cascade of secondary injury mechanisms that unfold in different phases within seconds of the primary trauma and continuing for several weeks thereafter. (B) Longitudinal section of the spinal cord after injury. The epicentre of the injury progressively expands after the primary trauma as a consequence of secondary injury events. This expansion causes an increased region of tissue cavitation and, ultimately, worsened long-term outcomes. Within and adjacent to the injury epicentre are severed and demyelinated axons. The neuroprotective agents listed act to subvert specific secondary injuries and prevent neural damage, while the neuroregenerative agents act to promote axonal regrowth once damage has occurred. ATP = adenosine triphosphate.
nisolone, started within 8 hours after injury, is a treatment option that should only be undertaken with knowledge of the potential complications.27

Other medications
Other treatments studied for neuroprotection include naloxone, an opioid antagonist that blocks the neurotoxic effects of the endogenous opioid dynorphin A;19,28 tirilazad, a nonlucocorticoid 21-aminosteroid developed to inhibit the peroxidation of neuronal membranes;29 and nimodipine, a calcium-channel blocker that prevents calcium-dependent activation of destructive cellular enzymes and presynaptic glutamate

**Table 1:** Pharmacologic agents evaluated in phase III trials for acute treatment of traumatic spinal cord injury

| Drug | Purported mechanism | No. of RCTs evaluating drug | Evidence for use |
|------|---------------------|----------------------------|-----------------|
| Methylprednisolone sodium succinate | • Attenuates peroxidation of the neuronal membrane  
• Reduces TNF-α release  
• Improves perfusion of spinal cord  
• Reduces influx of neuronal calcium | 3 (evaluating high-dose 24-h infusion v. placebo)19-21  
1 (evaluating high-dose 48-h infusion v. high-dose 24-h infusion)21 | High-dose 24-h infusion:*  
• No difference in NASCIS motor score recovery v. placebo in overall analysis (weighted MD 0.85 [95% CI –1.79 to 3.49])  
• Improved NASCIS motor score recovery in subgroup receiving treatment within 8 h of injury v. placebo (weighted MD 4.06 [95% CI 0.58 to 7.55])  
• Trend toward increased wound infection rates (RR 2.11 [95% CI 0.81 to 5.49]) and GI bleeding (RR 2.18 [95% CI 0.80 to 5.93]) in steroid group  
High-dose 48-h infusion:  
• No difference in NASCIS motor score recovery in overall analysis v. 24-h infusion (MD 3.37 [95% CI –0.54 to 7.28])  
• Trends toward increased rates of severe sepsis (RR 4.0 [95% CI 0.45 to 35.38]) and pneumonia (RR 2.25 [95% CI 0.71 to 7.15]) v. 24-h infusion |
| Naloxone | • Blocks the neurotoxic effects of the endogenous opioid dynorphin A | 1 (v. placebo)19 | • No difference in NASCIS motor score recovery between treatment and placebo groups |
| Nimodipine | • L-type calcium-channel blocker  
• Prevents activation of calcium-dependent apoptotic enzymes and blocks presynaptic release of glutamate | 1 (v. placebo)21 | • No difference in motor neurologic status between treatment (ASIA motor score 67 [95% CI 50 to 95]) and placebo groups (ASIA motor score 72 [95% CI 50 to 94]) at 1 year |
| Tirilazad mesylate | • Attenuates peroxidation of neuronal membrane | 1 (v. 24-h infusion of methylprednisolone)19 | • No difference in NASCIS motor score recovery between tirilazad and 24-h infusion of methylprednisolone  
• No placebo-controlled evaluation available |
| GM-1 ganglioside (Sygen) | • Important component of CNS neuronal membranes  
• Facilitates regrowth and regeneration of axons  
• Several neuroprotective properties | 1 (v. placebo)22 | • No difference in marked neurologic recovery between treatment and placebo groups as defined by at least a 2-grade improvement in modified Benzal scale§ grade |

Note: ASIA = American Spinal Injury Association, CI = confidence interval, GI = gastrointestinal, CNS = central nervous system, MD = mean difference, NASCIS = National Acute Spinal Cord Injury Study, RCT = randomized controlled trial, RR = relative risk, TNF = tumour necrosis factor.

*Results of a meta-analysis combining the results of 3 studies.
†Ordinal score between 0 and 35 reflecting the motor power in 7 key muscle groups on the right side of the body. A higher score suggests better motor function.
‡Ordinal score between 0 and 100 reflecting the motor power in 10 key muscle groups on both sides of the body. A higher score suggests better motor function.
§Ordinal scale between 1 and 7. A higher score suggests superior neurologic status.
regeneration after injury. In addition, a variety of neuroprotective effects have been attributed to these compounds. However, a randomized placebo-controlled trial of the ganglioside compound GM-1 (Sygen) involving 760 patients reported no difference in the proportion of patients achieving marked neurologic recovery at 6 months, although quantitative results were not presented.

What drugs are in development for treating spinal cord injury?

Several neuroprotective and neuroregenerative agents targeting specific pathological mechanisms are currently in the midst of clinical translation. Although promising, these agents have yet to show efficacy in phase III trials.

Neuroprotective agents

Riluzole
Riluzole is a sodium-channel blocker approved by the US Food and Drug Administration and Health Canada for the treatment of amyotrophic lateral sclerosis (ALS), in which it reduces motor neuron degeneration, thereby prolonging survival. In preclinical models of spinal cord injury, riluzole mitigates secondary injury by blocking pathological activation of sodium channels and reducing the release of neuronal glutamate. A phase I/II trial evaluating the safety and pharmacokinetics of riluzole for injuries in humans began in 2010 and was completed in January 2012, with full results awaiting publication.

Minocycline
Minocycline, a chemically modified form of tetracycline, has shown to be neuroprotective in animal injury models, although its exact mechanisms of action remain incompletely understood. Its use in other clinical conditions, such as acne, shows it has a favourable safety profile in humans. In a randomized placebo-controlled phase II trial, minocycline was associated with a trend toward improved motor recovery at 1 year (difference in American Spinal Injury Association motor score 6 points, 95% CI –3 to 14, p = 0.20). A single case of transiently elevated serum transaminases was the only drug-related complication reported.

Basic fibroblast growth factor
Injection of basic fibroblast growth factor has been shown to improve functional and respiratory parameters in animal injury models, presumably by reducing glutamate-mediated excitotoxicity. A recombinant version of this molecule is the subject of a phase I/II trial currently recruiting patients.

Neuroregenerative agents

Cethrin
BA-210 is a bacterial-derived toxin that inhibits the Rho pathway of inhibitory proteins and promotes axonal growth in vitro. When combined with a biohemostatic adhesive, BA-210 forms a permeable paste called Cethrin that is applied to the dura of the spinal cord postinjury. Based on documentation of preclinical efficacy, a phase I/IIa trial was undertaken during which 1 of 2 Cethrin dosages was applied to the dura during surgery in 48 patients with complete injuries. No serious complications were attributed to Cethrin at 1-year follow-up. Furthermore, among patients receiving doses of 1 and 3 mg, those with cervical injuries showed improvement on the American Spinal Injury Association motor score (mean of 27 points for patients in the 1 mg group and 21 points for patients in the 3 mg group). Such improvements compare favourably to the 10 points of motor recovery reported for similar patients in historical case series.

Anti-Nogo
Nogo-A is a protein that has been shown to block axonal growth in the human CNS. Anti-Nogo is a monoclonal antibody engineered to target Nogo-A and promote neural regeneration. This drug is currently in the early stages of clinical investigation.

What is the current status of cellular transplantation as a treatment option?

The transplantation of stem cells and autologous non–stem cells has been intensively studied in preclinical injury models. Various cellular subtypes have been used for this purpose, seeking optimal balance of the one or more key mechanisms through which each is theorized to act (release of growth-promoting trophic factors, environmental modification [i.e., reduction of scar or inflammation] and cellular replacement). In preclinical studies, cellular transplantation, either alone or in combination with other therapies, has been associated with enhanced neurobehavioural recovery, with no single cellular subtype showing superiority. Although prematurely used to treat patients with spinal injuries in several countries, no study has established efficacy for the transplantation of any cellular line. However, in the existing early phase trials, major
adverse events related to transplantation have been rare. When interpreting the results of clinical studies involving transplantation of cellular subtypes (Table 2), it is important to consider that, independent of treatment, most patients will undergo some natural neurologic recovery that will plateau 4–6 months after injury. For noncontrolled studies in which patients receive transplants before this plateau, it is impossible to discern whether improvements are related to treatment or simply to the patient’s natural recovery potential. For this reason, results must be interpreted with caution.

| Type of cell | Clinical studies published or underway | Patient population and time of cell administration | Results |
|--------------|----------------------------------------|------------------------------------------------------|---------|
| Bone marrow–derived stem cells | Geffner et al. 2008* Autologous cells given via intraspinal injection, IV or topically | 8 patients: 4 with acute injury (5 d–6 mo), 4 with chronic injury (5–21 yr) | No major adverse events; improvements in quality of life as measured by Barthel scale* and bladder function (quantitative results not reported) |
| | Yoon 2007†† Autologous cells with GM-CSF injected at site of lesion | 35 patients: 17 acute (< 2 wk), 6 subacute (2–8 wk), 12 chronic (> 8 wk) | No major adverse events in patients given implants; at least 1-grade improvement in AIS† in 30.4% of patients v. 0% in historical cohort |
| | Sykova 2006‡‡ Autologous cells given IA or IV | 20 patients: 7 acute (10–30 d), 13 chronic (2–17 mo) | No major adverse events; 5/7 acute patients and 1/13 chronic patients underwent neurologic improvement |
| | Deda 2008§§ Autologous cells via intraspinal injection | 9 patients with chronic complete injury | All patients improved by at least 1 AIS grade; no complications reported |
| | Olfactory ensheathing cells | Mackay-Sim 2008** Autologous cells injected intraspinally | 6 patients with chronic (> 6 mo) complete thoracic injury | No adverse events; no functional improvement; 1 patient had sensory improvement |
| | Lima 2010*** Olfactory mucosa containing cells injected intraspinally | 20 patients with chronic (18–89 mo) complete injury | 1 case of aseptic meningitis; at least 1-grade improvement in AIS 55% of patients |
| Schwann cells | Saberi 2008†† Autologous cells obtained from sural nerve and injected intraspinally | Interim safety report of 4/33 patients with chronic (28–80 mo) thoracic injury | No major adverse events; transient paresthesia and muscle spasms noted in all 4 patients |
| Activated autologous macrophages | Knoller 2005††† Cells injected intraspinally immediately caudal to lesion | 8 patients with acute (< 14 d) complete injury | No major adverse events related to implantation; at least 2-grade improvement in AIS in 3 patients (38%) |
| | Lammertse 2012‡‡‡ Cells injected intraspinally immediately caudal to lesion | 43 patients (26 treatment, 17 control) with acute (< 14 d) complete injury | At least 1-grade improvement in AIS in 7 patients in treatment group (27%) and 10 patients in control group (59%); 1 case of postoperative spinal instability, 1 case of postoperative atelectasis attributed to treatment |
| Human embryonic stem cells | Geron Corp., Menlo Park, CA Cells injected intraspinally | Target enrolment of 8 patients with acute (7–14 d) complete thoracic injury | Trial stopped before completion after implantation in 4 patients |
| Tissue-derived adult neural stem cells | Curt (ongoing) Allogeneic cells injected intraspinally | Target enrolment of 12 patients with chronic (> 6 wk) thoracic injury | Currently enrolling, no data reported |

Note: AIS = American Spinal Injury Association Injury Scale, GM-CSF = granulocyte macrophage colony-stimulating factor, IA = intraarterial, IV = intravenous. *Ordinal scale between 1 and 10. A high score suggests a high likelihood of living at home and functioning independently. †Scale with 5 levels ranging from grade A (most severe) to E (perfect neurologic status).
Overall, cellular transplantation is purely an investigational therapy, which should currently only be undertaken in the context of clinical trials.

Future directions

Box 2 provides a fictional case in which the results of this review are applied in clinical practice. Recent laboratory work has identified other promising therapies yet to appear on the clinical landscape. Chondroitinase ABC is a bacterial-derived enzyme that has shown beneficial effects in rodent injury models by degrading elements of the glial scar preventing post-traumatic axonal growth. When combined with magnesium, the hydrophilic polymer polyethylene glycol has shown neuroprotective properties in animal models by preserving neuronal membrane integrity. Both of these treatments appear poised for eventual translation to the clinic.

More recently, several groups have begun to investigate the role of nanomedicine in promoting neuroprotection and neuroregeneration after injury. Ceramide and gold nanoparticles have shown positive results both in vitro and in vivo. Finally, apart from pharmacologic therapies, researchers are in the early phases of investigating neuromodulatory approaches such as epidural spinal cord stimulation to aid rehabilitation efforts during the chronic phases after injury. Although only described in the form of case reports, such approaches appear promising and may someday augment the benefits contributed by acute therapeutics to maximize patients’ long-term potential for recovery.

References

1. Noonan VK, Fingas M, Farry A, et al. The incidence and prevalence of spinal cord injury in Canada: a national perspective. Neuroepidemiology 2012;38:219-26.
2. Farry A, Baxter D. The incidence and prevalence of spinal cord injury in Canada: overview and estimates based on current evidence. Vancouver (BC): Rick Hansen Institute and Urban Futures; 2010. Available: www.urbanfutures.com/reports/Report%2080.pdf (accessed 2011 June 15).
3. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26.
4. Schwartz G, Fehlings M. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res 2002;137:177-90.
5. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol 2008;209:294-301.
6. Fehlings MG, Theodore N, Harrop J, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 2011;28:787-96.
7. Wilson JR, Fehlings MG. Emerging approaches to the surgical management of acute traumatic Spinal Cord Injury. Neurotherapeutics 2011;8:187-94.
8. Chersnt RM, Marshall L, Klauber M, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993;34:216-22.
9. Levi L, Wolf A, Belzber H. Hemodynamic parameters in patients with acute cervical cord trauma: description, intervention, and prediction of outcome. Neurosurgery 1993;33:1007-1016.
10. Blood pressure management after acute spinal cord injury. Neurosurgery 2002;50:S58-62.
11. Management of acute spinal cord injuries in an intensive care unit or other monitored setting. Neurosurgery 2002; (Suppl 3): S51-7.
12. Furlan JC, Noonan V, Cadotte DW, et al. Timing of decompressive surgery of spinal cord after traumatic spinal cord injury: an evidence-based examination of pre-clinical and clinical studies. J Neurotrauma 2011;28:1371-99.
13. Bedbrook GM, Sedgley GI. The management of spinal injuries — past and present. Int Rehabil Med 1980;2:45-61.
14. Fehlings MG, Perrin BG. The timing of surgical intervention in the treatment of spinal cord injury: a systematic review of recent clinical evidence. Spine (Phila Pa 1976). 2006;31(Suppl 11):S28-35; discussion S6.
15. Fehlings MG, Vaccaro A, Wilson J, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS ONE 2012;7:e32037.
16. Fehlings MG, Rabin D, Sears W, et al. Current practice in the timing of surgical intervention in spinal cord injury. Spine 2010; 35:S166-73.
17. Lo TP Jr, Cho KS, Garg MS, et al. Systemic hypothermia improves histological and functional outcome after cervical spinal cord contusion in rats. J Comp Neurol 2009;514:433-48.
18. Levi AD, Casella G, Green BA, et al. Clinical outcomes using modest intravascular hypothermia after acute cervical spinal cord injury. Neurosurgery 2010;66:670-7.
19. Bracken MB, Shepard M, Collins W, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
20. Otani K, Abe H, Kadoya S. Beneficial effects of methylprednisolone sodium succinate in the treatment of acute spinal cord injury. Sekity Sekizui 1994;7:633-47.
21. Petjean ME, Pontillant V, Dimmerias F, et al. Medical treatment
of spinal cord injury in the acute stage. Ann Fr Anesth Reanim 2012;31:171-5.
22. Bracken MB, Shepard M, Hol福德 T, et al. Administration of methylprednisolone for 24 or 48 hours or tirilizad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-604.
23. Geisler FH, Coleman W, Grieco G, et al. The Sygen multicenter acute spinal cord injury study. Spine 2001;26:S79-87.
24. Braugher JM, Hall E. Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neuronfibrilament degradation and energy metabolism. J Neurosurg 1984;61:5.
25. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012;1:CD001046.
26. Hurtbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000;93:1-7.
27. Hugenholtz H, Cass D, Dvorak M. High-dose methylprednisolone for acute closed spinal cord injury — only a treatment option. Can J Neurol Sci 2002;3:227-35.
28. Baskin DS, Simpson RK Jr, Browning JL, et al. The effect of long-term high-dose naloxone infusion in experimental blunt spinal cord injury. J Spinal Disord 1993;6:38-43.
29. Fehlings MG, Tator CH, Linden RD. The effect of nimodipine sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg 1989;71:403-16.
30. Bose B, Osterholm J, Kalia M. Ganglioside-induced regeneration and reestablishment of axonal continuity in spinal cord transected rats. Neurosci Lett 1986;63:165-9.
31. Miller RG, Mitchell JD, Lyon M, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;(1):CD001447.
32. Fehlings MG, Wilson JR, Frankowski RF, et al. Riluzole for the treatment of acute traumatic spinal cord injury. Lancet 2001;358:1966-73.
33. Grossman RG, Fehlings MG, Frankowski RF, et al., editors. A phase II multicenter trial to investigate the safety and pharmacokinetics profile of riluzole in the treatment of traumatic spinal cord injury. Proceedings of the Society for Neuroscience 12 meeting; 2012 Oct 14; New Orleans.
34. Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotection and reestablishment of axonal continuity in spinal cord injured patients: rationale for and design of the NACTN Phase I Clinical Trial. J Neurosurg Spine 2012;17:151-6.
35. Grossman RG, Fehlings MG, Frankowski RF, et al., editors. A phase I/II multicenter trial to investigate the safety and pharmacokinetics profile of riluzole in the treatment of traumatic spinal cord injury. Proceedings of the Society for Neuroscience 12 meeting; 2012 Oct 14; New Orleans.
36. Casha S, Zygun D, McGowan M, et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 2012;135:1224-36.
37. Teng YD, Mocchetti I, Taveira-DaSilva AM, et al. Basic fibroblast growth factor increases long-term survival of spinal motor neurons and improves respiratory function after experimental spinal cord injury. J Neurosci 1999;19:7037-47.
38. Spillmann AA, Bandlow CE, Lottspeich F, et al. Identification and characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 1998;273:19283-93.
39. Freund P, Wanner T, Schmidlin E, et al. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 2007;502:644-59.
40. Geffner LF, Santacruz P, Irazueta M, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant 2008;17:1277-93.
41. Yoon SH, Shim YS, Park YH, et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase II clinical trial. Stem Cells 2007;25:2066-73.
42. Sykora E, Hornola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006;15:675-87.
43. Deda H, Inci MC, Kurelci AE, et al. Treatment of chronic spinal cord injury in patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy 2010;8:565-74.
44. Mackay-Sim A, Feron F, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain 2008;131:2376-86.
45. Lima C, Escada P, Pratas-Vital J, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair 2010;24:10-22.
46. Saberi H, Mooshayed P, Aghayan HR, et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett 2008;443:46-50.
47. Knolz N, Auerbach G, Fulga V; et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005;3:173-81.
48. Lampl R, Matthews PM, Jones LA, Charlutfie SB, et al. Autologous incubated macrophase therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord 2012;50:661-71.
49. Bradbury EJ, Carter LM. Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res Bull 2011;84:306-16.
50. Luo J, Borgens R, Shi R. Polyethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury. J Neurochem 2002;83:471-80.
51. Das M, Patil S, Bhargava N, et al. Auto-catalytic ceria nanoparticle offers neuroprotection to adult rat spinal cord neurons. Biomaterials 2007;28:1918-25.
52. Harkema S, Gerasimenko Y, Hodes J, et al. Effect of epidural stimulation of the lumbar spinal cord on voluntary movement, standing, and assisted stepping after motor complete para-plegia: a case study. Lancet 2011;377:1938-47.

Affiliation: From the Department of Surgery (Wilson, Forgeine, Fehlings), Division of Neurosurgery and Spinal Program, University of Toronto, Toronto, Ont.

Contributors: All of the authors contributed substantially to the conception and design of the study, to the drafting and critical revision of the article for important intellectual content and to the final approval of the published version.

Acknowledgement: Jefferson Wilson received postdoctoral fellowship support from the Christopher and Dana Reeve Foundation.